Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.38. Which is the better fit depends on your goals.
| ALNY | SOXS | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $160.60 |
52-Week Low | $278.09 | $3.25 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, trades at $4.08 with minimal daily movement (+0.25%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The ETF is preparing for a 1:10 stock split effective July 15, 2026, and declared a $0.04 dividend for H1-2026. Recent news highlights the challenging environment for bearish semiconductor bets amid an ongoing AI-driven chip rally that has pressured inverse ETFs.
The outlook for SOXS remains highly speculative and risky, suitable only for sophisticated traders seeking short-term inverse exposure to semiconductors. The primary opportunity lies in potential semiconductor sector volatility or correction, while significant risks include continued AI-driven bullish momentum and the structural decay inherent in leveraged inverse ETFs during sustained market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
